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EXPERIMENTAL STUDIES
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Angiotensin-Converting Enzyme Inhibition in Heart
Failure Improves Endothelial Vasomotor Dysfunction
Role of Vascular Superoxide Anion Formation
and Endothelial Nitric Oxide Synthase Expression
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OBJECTIVES We sought to investigate the effects of adding spironolactone (SP) to angiotensin-converting
enzyme (ACE) inhibition on endothelium-dependent vasodilation in rats with chronic heart
failure (CHF).
BACKGROUND Adding SP to ACE inhibitors reduces mortality and morbidity in CHF. Endothelial
vasomotor dysfunction contributes to increased peripheral vascular resistance and reduced
myocardial perfusion in CHF.
METHODS Seven days after extensive myocardial infarction (CHF) or sham operation, Wistar rats were
treated with placebo, the ACE inhibitor trandolapril (TR, 0.3 mg/kg body weight per day),
SP (10 mg/kg per day) or a combination of both for 11 weeks.
RESULTS Maximal acetylcholine-induced, nitric oxide (NO)-dependent relaxation was significantly
attenuated in aortic rings from rats with CHF as compared with sham-operated animals
(Rmax 44  3% vs. 63  3%). Spironolactone alone had no influence (46  5%) and TR
improved NO-mediated relaxation (55  4%), whereas treatment with both completely
restored endothelium-dependent vasorelaxation (64  4%). Aortic superoxide formation was
significantly increased in rats with CHF as compared with sham-operated animals, but was
normalized by treatment with SP or SP plus TR. In addition, aortic messenger ribonucleic
acid expression of the oxidase subunit p22phox in rats with CHF was significantly reduced by
SP or TR plus SP. Endothelial NO synthase expression was increased in TR-treated animals.
Incubation of isolated porcine coronary arteries with SP dose-dependently attenuated
superoxide formation.
CONCLUSIONS Spironolactone added to an ACE inhibitor normalizes NO-mediated relaxation in experi-
mental CHF by beneficially modulating the balance of NO and superoxide anion
formation. (J Am Coll Cardiol 2002;39:351–8) © 2002 by the American College of
Cardiology
The endothelium plays a crucial role in the control of
vascular tone by releasing endothelium-derived autacoids,
the most important of which is nitric oxide (NO) (1). A
reduced bioavailability of NO has been reported in cardio-
vascular diseases such as arterial hypertension, arterioscle-
rosis and diabetes (2), supporting the important role of NO
in cardiovascular pathophysiology. In chronic heart failure
(CHF), a reduced bioavailability of NO in the peripheral
and coronary arteries increases peripheral vascular resistance
and reduces myocardial perfusion, contributing to reduced
myocardial function (3–7). As oxidative stress is increased in
patients with CHF (8,9) and superoxide anion (O2
)
rapidly scavenges NO in the vascular wall, a reduction of
bioactive NO may occur, despite normal or even increased
NO generation (10). Indeed, endothelial dysfunction coin-
cided with an increase in vascular endothelial NO synthase
(eNOS) expression and a concomitant increase in O2

generation, leading to a reduced NO bioavailability in
experimental CHF (11).
Mortality of patients with CHF has been reduced by
treatment with angiotensin-converting enzyme (ACE) in-
hibitors, which may be explained, at least in part, by an
improvement of endothelial function and subsequent im-
provement of perfusion and exercise capacity (12–14).
However, morbidity and mortality of patients with CHF
remain high. Increased plasma levels of aldosterone are
considered to be an independent risk factor for a worse
outcome in patients with CHF (15). Originally, it has been
assumed that ACE inhibitors block angiotensin II–
dependent adrenal aldosterone secretion. However, an “al-
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dosterone escape” occurs (16). The clinical relevance of this
observation has been supported by the convincing results of
the recently published Randomized ALdactone Evaluation
Study (RALES), in which the mineralocorticoid receptor
antagonist spironolactone (SP) was added to ACE inhibi-
tion in patients with severe CHF, markedly reducing overall
mortality by 30% (17) and improving endothelium-
dependent NO formation (18). However, the mechanisms
involved in the beneficial effects of SP on endothelium-
dependent dilation remain unknown.
Therefore, we investigated the effect of long-term treat-
ment with low-dose SP (19) and the ACE inhibitor
trandolapril (TR), either alone or in combination, on
endothelium-dependent and -independent relaxant re-
sponses in the aorta of rats with CHF after experimental
myocardial infarction (MI). In addition, the formation of
aortic O2
 and the expression of p22phox, the critical
subunit of NADPH oxidase, and eNOS were assessed.
METHODS
Study protocol, MI and hemodynamic measurements.
Left coronary artery ligations were performed in adult male
Wistar rats weighing 250 to 300 g, as previously described
(20). Briefly, the thorax was opened under ether anesthesia;
the heart was exteriorized; and a ligature was placed around
the proximal left coronary artery. On the seventh postoper-
ative day, surviving rats were randomly allocated to placebo,
the ACE inhibitor TR (0.3 mg/kg body weight per day), SP
(10 mg/kg per day) or a combination of TR and SP.
Hemodynamic studies were performed 12 weeks after cor-
onary artery ligation under barbiturate anesthesia and con-
trolled respiration (20). Drug treatment was withheld for
24 h before hemodynamic studies to exclude acute drug
effects.
Sample collection, determination of infarct size and
ventricular remodeling. After hemodynamic measure-
ment, the heart was flushed in ice-cold Krebs-Ringer
solution, and the left ventricle was the cut into three
transverse sections: the apex, middle ring (3 mm) and base.
From the middle ring, 5-m sections were cut at 100-m
intervals and stained with picrosirius red. The boundary
length of the infarct-related and non–infarct-related sur-
faces of the endocardium and epicardium were traced with
a planimeter digital image analyzer, and infarct size (fraction
of the infarct-related left ventricle) was expressed as a
percentage of length. Only rats with extensive infarcts
(40%) were included in the study of vascular reactivity.
Vascular reactivity studies. The descending thoracic aorta
was dissected and cleaned of connective tissue. The upper
section (10 mm) was immediately frozen for Western blot
and polymerase chain reaction (PCR) analysis. The lower
section (10 mm) was used for measurement of O2
 produc-
tion, whereas the remainder was cut into 3-mm rings, which
were mounted in an organ bath (FMI, Seeheim, Germany)
for isometric force measurements. The rings were equili-
brated for 30 min under a rest tension of 2 g in oxygenated
(95% oxygen and 5% carbon dioxide) Krebs-Henseleit
solution (measurements in mmol/l: NaCl 118, KCl 4.7,
MgSO4 1.2, CaCl2 1.6, K2HPO4 1.2, NaHCO3 25, glucose
12; pH 7.4; 37°C) containing diclofenac (1 mol/l) (21).
The rings were repeatedly contracted by KCl (100 mmol/l)
until reproducible responses were obtained. Thereafter, the
rings were preconstricted with phenylephrine (0.3 to 1.0
mol/l) to comparable constriction levels, and the relaxant
response to cumulative doses of acetylcholine and sodium
nitroprusside was assessed (22).
Porcine coronary arteries. Coronary arteries of porcine
hearts (obtained from a local slaughterhouse) were cau-
tiously dissected free of the adhering fat and connective
tissue. Small segments (3 to 4 mm in length) were
cultured in phenol red–free medium 199 (cc pro, Neustadt,
Germany) containing polymyxin B (5 g/ml) and penicil-
lin/streptomycin (10 IU/ml and 10 g/ml, respectively).
The rings were incubated with SP, RU486, progesterone,
cortisol, aldosterone or vehicle alone (control) up to 48 h.
Measurement of O2
 formation. Vascular O2
 formation
was measured using lucigenin-enhanced chemiluminescence
(21). The light reaction between O2
 and lucigenin (5 or
250 mol/l [23]) was detected by a luminometer (Wallac,
Freiburg, Germany) during incubation of the rings in a
HEPES-modified Krebs buffer (pH 7.40). The specific
signal was expressed as counts per minute per milligram of
dry weight of tissue (cpm/mg).
Western blot analysis. Rat aortae were homogenized, and
crude protein extracts (20 g) were subjected to sodium
dodecyl sulfate–polyacrylamide gel electrophoresis. Endo-
thelial NOS protein was detected using a specific antibody
(Transduction Laboratories, Lexington, Kentucky). En-
hanced chemiluminescence (Pharmacia Biotech, Freiburg,
Germany) was visualized, and the signals were densito-
metrically determined by the National Institutes of Health
(NIH) Image software (version 1.62).
Quantification of messenger ribonucleic acid (mRNA)
expression by competitive reverse transcription (RT)-
PCR. Vascular mRNA expression of eNOS, p22phox and
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
was determined by competitive PCR. Total RNA was
isolated using Trizol reagent (Life Technologies, Eggen-
stein, Germany). After RT (Advantage RT-for-PCR Kit,
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  chronic heart failure
eNOS  endothelial nitric oxide synthase
MI  myocardial infarction
NO  nitric oxide
O2
  superoxide anion
RT-PCR  reverse transcription polymerase chain
reaction
SP  spironolactone
TR  trandolapril
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Clontech Inc., Palo Alto, California), first-strand comple-
mentary deoxyribonucleic acid (cDNA) was used as a
template for PCR. Nonhomologous internal standards with
primer templates that are recognized by the gene-specific
primers were constructed (PCR MIMIC Construction Kit,
Clontech Inc.), and cDNA was incubated with decreasing
amounts of known standards and amplified with gene-
specific primers. Products of PCR amplification were sep-
arated on 1.5% (wt/vol) agarose gel preparations, and
expression levels of ethidium-stained products of the tem-
plates and standards were densitometrically determined
using the NIH Image software (version 1.61). Absolute
expression levels were calculated by comparison with the
signals of equimolar amounts of the standard.
Materials. All biochemicals were obtained from Sigma
(Deisenhofen, Germany). Spironolactone was provided by
Pharmacia (Erlangen, Germany), and TR by Knoll AG
(Ludwigshafen, Germany).
Statistics. Relaxant responses were given as percent relax-
ation relative to the preconstriction level. Data are expressed
as the mean value  SEM of n experiments with segments
from different arteries. Statistical analysis was performed by
one-way analysis of variance, followed by the Tukey-
Kramer multiple comparisons test or the two-tailed Student
t test for unpaired data, as appropriate. A p value0.05 was
considered statistically significant.
RESULTS
Global variables. Global variables of rats with CHF and
sham-operated animals are shown in Table 1. Infarct sizes
were comparable among the different experimental groups.
Left ventricular systolic pressure was significantly lower in
all groups of rats with CHF, whereas left ventricular
end-diastolic pressure was markedly elevated.
Vasodilator responses in aortic rings. Acetylcholine in-
duced a concentration-dependent relaxation of the aortic
rings preconstricted with phenylephrine. Receptor-
dependent relaxation was reduced in the aortae of rats with
heart failure after extensive MI (Fig. 1A and Table 2).
Long-term treatment with SP alone had no effect on
acetylcholine-induced relaxation, whereas TR slightly im-
proved endothelium-dependent relaxation (Fig. 1A and
Table 2). Treatment of rats with a combination of SP and
TR led to restoration of the acetylcholine-induced relax-
ation in the aortic rings of rats with CHF (Fig. 1A and
Table 2). The concentration-response curve of the
endothelium-independent vasodilator sodium nitroprusside
was not different between sham-operated animals and rats
with CHF (Fig. 1B and Table 2). The concentration-
response curve to sodium nitroprusside in the aortae of rats
treated with SP alone was shifted to the right, whereas
endothelium-independent relaxation was similar in all other
treatment groups (Fig. 1B and Table 2).
Superoxide anion formation and p22phox expression in
the rat aorta. Formation of O2
 was significantly increased
in the aortae of rats with CHF as compared with sham-
operated rats. Formation of O2
 was reduced in the aortae
of TR-treated rats, whereas generation of O2
 was com-
pletely normalized in all rats treated with SP (measurements
in cpm/mg—sham/placebo: 651  32; CHF/placebo:
1,066  119; CHF/SP: 591  104; CHF/TR: 831  85;
CHF/TRSP: 581  79) and lucigenin, 250 mol/l.
Similar results were obtained in a separate series of experi-
ments using 5 mol/l of lucigenin (Fig. 2).
Vascular mRNA expression of p22phox was significantly
reduced in rats with CHF treated with SP alone or in
combination with TR (2.1  0.2 and 1.9  0.3 attomol/g
RNA), as compared with the other groups (sham/placebo:
2.9  0.2; CHF/placebo: 3.7  0.3; CHF/TR: 3.2  0.5
attomol/g RNA; p  0.05), whereas mRNA expression of
GAPDH was not changed (sham/placebo: 51  9; CHF/
placebo: 54  10; CHF/TR: 50  4; CHF/SP: 53  13;
CHF/TRSP: 54  7 nmol/g RNA).
Expression of eNOS in the rat aorta. There was a trend
toward increased mRNA expression of vascular eNOS in
rats with CHF treated with TR, either alone or in combi-
nation with SP (5.1 1.0 and 5.4 1.1 attomol/g RNA),
as compared with the other experimental groups (sham/
placebo: 4.1  0.2; CHF/placebo: 4.4  0.1; CHF/SP:
4.2  0.2 attomol/g RNA). Endothelial NOS protein
expression was elevated in rats with CHF as compared with
sham-operated rats, as previously shown (11). Furthermore,
eNOS protein expression was significantly higher in rats
with CHF treated with TR, alone or in combination with
SP, whereas eNOS expression tended to be reduced in rats
with CHF treated with SP alone (Fig. 3).
Direct actions of SP and steroids on vascular radical
generation. In porcine coronary artery segments, basal
superoxide anion generation was 862  75 cpm/mg (n 
67) after culturing them for 48 h (lucigenin, 250 mol/l).
Table 1. Variables in Rats With Chronic Heart Failure at 12 Weeks After Myocardial
Infarction, as Compared With Sham-Operated Animals
Sham/Placebo
Group (n  10)
CHF/Placebo
Group (n  10)
CHF/TR
Group (n  8)
CHF/SP
Group (n  8)
CHF/TR  SP
Group (n  8)
Infarct size (%) — 47  1 50  1 50  1 48  2
LVSP (mm Hg) 141  5 116  3* 119  3* 112  5* 110  7*
LVEDP (mm Hg) 5.6  0.3 23  3* 18  3 18  3 12  4
*p  0.05 vs. sham/placebo group. Data are presented as the mean value  SEM. Rats were treated with either placebo,
trandolapril alone (TR, 0.3 mg/kg body weight per day), spironolactone alone (SP 10 mg/kg per day) or a combination of both.
CHF  chronic heart failure; LVSP  left ventricular systolic pressure; LVEDP  left ventricular end-diastolic pressure;
SP  spironolactone; TR  trandolapril.
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The addition of the flavoprotein inhibitor diphenyleneiodo-
nium (10 mol/l; 65  62 cpm/mg; n  7) significantly
reduced any lucigenin-detectable chemiluminescence,
whereas the addition of the radical scavenger tiron (10
mmol/l; n  6) completely abrogated it (data not shown).
Co-incubation of rings with 10 nmol/l of SP for 48 h
significantly attenuated O2
 generation as compared with
respective control rings (427  82 vs. 715  87 cpm/mg; n
 7). Similar results were obtained using 5 mol/l of
lucigenin (Fig. 4). A reduction of vascular O2
 generation
by SP was dose-dependent (median effective concentration
[EC50]: 1 nmol/l), reaching near maximal effects at 10
nmol/l. Acute addition of NADH (100 mol/l) signifi-
cantly increased O2
 formation, as compared with basal
conditions (lucigenin, 5 mol/l) (Fig. 4). NADH-
stimulated O2
 formation was significantly attenuated in
rings co-incubated with SP (Fig. 4). Spironolactone did not
affect O2
 generation after short-term (30 min) incubation
Figure 1. Relaxations induced by acetylcholine (A) and sodium nitroprusside (B) in the aortic rings of rats with congestive heart failure (CHF) at 12 weeks
after myocardial infarction (solid circles, diamonds, triangles and squares), as compared with sham-operated animals (open circles). The animals were
treated with either placebo (Plac; solid and open circles), trandolapril (TR) (0.3 mg/kg body weight per day; solid diamonds), spironolactone (SP) (10
mg/kg per day; solid triangles) or a combination of TR and spironolactone (SP) (solid squares). Data are presented as the mean value  SEM from 8 to
10 separate experiments. **p  0.01 CHF/placebo group vs. sham/placebo group and CHF/TR-SP group.
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of coronary segments. Furthermore, adding SP directly to
the test tube did not affect the chemiluminescence signal,
excluding any direct quenching effect of the drug.
Culture of coronary rings in either aldosterone (10
nmol/l; 1,169  133 cpm/mg) or hydrocortisone (10
nmol/l; 996 149 cpm/mg) did not modulate vascular O2

formation, as compared with control conditions (1,146 
152 cpm/mg; n  16 to 19), whereas incubation in
progesterone (10 nmol/l; 541  70 cpm/mg) and RU486
(10 mol/l; 509  60 cpm/mg) significantly reduced O2

formation, as compared with respective control conditions
(818  147 cpm/mg; n  19). Attenuation of O2

generation by progesterone or SP was not further modulated
by co-incubation with RU486 (progesterone: 571  76
cpm/mg; SP: 448  59 cpm/mg; n  19).
DISCUSSION
In the present study, adding SP to ACE inhibitor treatment
completely restored the attenuated endothelium-dependent
relaxation in rats with experimental CHF, whereas SP alone
did not modulate it, and TR alone only slightly improved
the endothelium-dependent vasodilator response. We ob-
served an upregulation of eNOS expression and a modest
reduction of vascular O2
 formation by the ACE inhibitor
TR , whereas SP significantly reduced vascular O2
 forma-
tion and p22phox expression. Spironolactone-induced effects
on vascular O2
 generation appear to be mediated by direct
actions on vascular radical generation, as demonstrated in
separate experiments in cultured rings of porcine coronary
arteries.
NO formation and eNOS expression in CHF. Impair-
ment of endothelium-dependent, NO-mediated vasorelax-
ation has been repeatedly reported in patients with CHF
(4,24), probably contributing to elevated vascular resistance.
Comparable results have been obtained in a rat model of
experimental CHF, where attenuation of endothelium-
dependent vasodilation has been reported in various vascular
beds (5,11,25,26). The decreased release of NO may be
Table 2. Acetylcholine- and Sodium Nitroprusside-Induced Relaxations in the Aortic Rings of
Rats With Chronic Heart Failure at 12 Weeks After Myocardial Infarction, as Compared With
Sham-Operated Animals
Sham/Placebo
Group
CHF/Placebo
Group
CHF/TR
Group
CHF/SP
Group
CHF/TR  SP
Group
ACh
ED50(log) 6.68  0.08 6.27  0.06* 6.42  0.09 6.35  0.08 6.43  0.06
Rmax 63  3% 44  3%* 55  4% 46  5%† 65  5%‡
SNP
ED50 (log) 7.57  0.07 7.69  0.08 7.63  0.09 7.27  0.11§ 7.59  0.09
Rmax 98  1% 96  1% 98  1% 94  2% 98  1%
*p  0.01 and †p  0.05 vs. sham/placebo group. ‡p  0.01 and §p  0.05 vs. CHF/placebo group. Data are presented as the
mean value  SEM. Rats were treated with either placebo, trandolapril (TR, 0.3 mg/kg body weight per day), spironolactone
alone (SP, 10 mg/kg per day) or a combination of both (n  8 to 10).
ACh  acetylcholine; ED50  median effective dose; SNP  sodium nitroprusside; other abbreviations as in Table 1.
Figure 2. Production of superoxide anion (O2
) (lucigenin 5 mol/l) in
the aortic rings of rats with congestive heart failure (CHF) at 12 weeks after
myocardial infarction, as compared with sham-operated animals (for
experimental groups, see Fig. 1). Data are presented as the mean value 
SEM from 8 to 10 separate experiments. **p  0.01 CHF/placebo group
vs. sham/placebo group. §p  0.01 CHF/spironolactone (SP) group and
CHF/trandolapril (TR)-SP group vs. CHF/placebo group.
Figure 3. Aortic endothelial nitric oxide synthase (eNOS) expression in
rats with congestive heart failure (CHF) at 12 weeks after myocardial
infarction (relative to the signals obtained in the sham-operated rats), as
compared with sham-operated animals (for experimental groups, see Fig.
1). Densitometric analysis (bottom; n  5 to 6) and a representative blot
(top). Data are presented as the mean value  SEM. *p  0.05 vs.
sham/placebo, CHF/placebo and CHF/spironolactone (SP) groups. TR 
trandolapril.
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explained by downregulation of eNOS, the key enzyme of
endothelial, receptor-dependent NO liberation. Indeed,
reduced vascular eNOS expression has been reported in
pacing-induced CHF in dogs and in monocrotaline-
induced pulmonary hypertension and CHF in rats (27,28).
However, in rats with ischemic heart failure after extensive
MI, NO-mediated relaxations are blunted, despite an in-
crease in aortic eNOS expression, presumably due to an
increased generation of superoxide radicals (11), leading to
a reduction of NO bioavailability.
Superoxide formation and NO-mediated relaxation in
CHF. A NAD(P)H-dependent vascular oxidase in the
aortic wall has been identified as a major source of increased
vascular O2
 generation in rats with chronic MI (11). In the
present study, we extend these findings, demonstrating
enhanced expression of p22phox, which is considered to be
the critical subunit for NAD(P)H-dependent oxidase activ-
ity (29). Elevated levels of angiotensin II upregulate vascular
subunit expression and increase oxidase activity (30). As
plasma renin activity, as well as tissue ACE activity, is
markedly elevated in rats with chronic MI (31), vascular
O2
 generation in rats with CHF may presumably be
induced by increased angiotensin II formation. Conforming
to this interpretation, TR may improve endothelial function
in our rat model of CHF by a reduction of angiotensin
II–dependent O2
 generation. However, SP alone induced
an even more pronounced attenuation of vascular O2

generation, as compared with TR, but had no effect on
acetylcholine-induced relaxation. An improvement of endo-
thelial function may be masked by reduced smooth muscle
responsiveness, as suggested by the rightward shift of the
concentration response curve to sodium nitroprusside. The
marked reduction of O2
 generation and p22phox expression
by SP, as compared with the modest effects of TR on O2

formation, suggests that vascular oxidant stress in CHF is
not solely dependent on angiotensin II–dependent mecha-
nisms in rats after extensive MI. Indeed, enhanced vascular
O2
 generation has also been observed in low-renin hyper-
tension (32), suggesting that increased vascular O2
 gener-
ation may be partially independent of angiotensin II.
Our data imply that ACE inhibition may improve endo-
thelial vasomotor dysfunction by an increase in endothelial-
dependent NO release, in addition to a reduction of O2

generation. Indeed, ramipril, at dosages that are not acting
as antihypertensive, increases eNOS expression and NO
synthesis in the carotid arteries and thoracic aortae of
spontaneously hypertensive rats (33). Because only the
combination of SP and TR was able to completely restore
NO-mediated relaxation in rats with CHF, we suggest that
both the marked increase in eNOS expression and activity
and the normalization of O2
 formation by SP may be
crucial for the beneficial effect on NO/O2
 balance.
Attenuation of vascular superoxide formation by SP.
One may speculate that increased plasma aldosterone levels,
even during ACE inhibition, induce endothelial dysfunc-
tion by an increased formation of superoxide anions. A
low-potassium diet markedly increases aortic superoxide
formation in rats; thus, the potassium-sparing effect of SP
may contribute to the reduction of O2
 generation in rats
with CHF (34). However, our rats were fed with standard
chow, and plasma K was not elevated by SP in a compa-
rable study setting (19). Furthermore, aldosterone may
directly act on the vasculature and increase vascular radical
generation. However, neither aldosterone nor cortisol in-
creased O2
 formation in isolated porcine coronary arteries,
whereas SP significantly attenuated radical generation.
Thus, an action of SP independent of mineralocorticoid
receptor antagonism may mediate a reduction of aortic O2

formation in rats with CHF and in isolated porcine coro-
nary arteries. This interpretation is supported by reduced
Figure 4. Generation of superoxide anion (O2
) in porcine coronary arteries cultured for 48 h in the absence (open bars) or presence of spironolactone
(10 nmol/l; closed bars). Generation of O2
 was determined at baseline and after addition of 100 mol/l nicotinamide adenine dinucleotide (NADH).
*p  0.05.
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O2
 formation in rings co-incubated with progesterone.
Those findings may point to involvement of the progesta-
genic actions of SP (35). However, we were not able to
prove this hypothesis, as the progesterone receptor antago-
nist RU486 displays comparable inhibitory effects on radical
generation.
Clinical implications. The beneficial modulation of NO/
O2
 balance observed in our study provides an explanation
for the improvement of endothelial function in patients with
CHF treated with SP in addition to ACE inhibition (18).
Thus, we speculate that SP may enhance tissue perfusion
and exercise capacity in patients with CHF by a reduction of
vascular O2
 generation, in addition to the beneficial effects
of ACE inhibition. A reduction of coronary O2
 generation
and subsequent improvement of endothelial function may
beneficially modulate left ventricular remodeling, probably
leading to a better quality of life and prognosis (7,36).
Conclusions. In experimental CHF, combination therapy
with SP and the ACE inhibitor TR restored endothelial
function more efficiently than the ACE inhibitor alone. A
better NO/O2
 balance is probably achieved by a marked
upregulation of eNOS expression by the ACE inhibitor TR
and a significant reduction of O2
 formation by SP. The
beneficial actions of SP in CHF (as demonstrated in
RALES) may be explained, at least in part, by the beneficial
effects on vascular radical generation.
Acknowledgments
The authors thank Elke Kirsch, Claudia Liebetrau and
Anna Dembny for their expert technical assistance, and
Prof. H. Basler and Prof. H. Vogt for their expert statistical
advice.
Reprint requests and correspondence: Dr. Johann Bauersachs,
Medizinische Universita¨tsklinik, Josef-Schneider-Str. 2, D-97080
Wu¨rzburg, Germany. E-mail: j.bauersachs@medizin.uni-
wuerzburg.de.
REFERENCES
1. Fleming I, Busse R. NO: the primary EDRF. J Mol Cell Cardiol
1999;31:5–14.
2. Drexler H, Hornig B. Endothelial dysfunction: a novel therapeutic
target—endothelial dysfunction in human disease. J Mol Cell Cardiol
1999;31:51–60.
3. Wang J, Sejedi N, Xu XB, Wolin MS, Hintze TH. Defective
endothelium-mediated control of coronary circulation in conscious
dogs after heart failure. Am J Physiol 1994;266:H670–80.
4. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM.
Endothelium-dependent vasodilation is attenuated in patients with
heart failure. Circulation 1991;84:1589–96.
5. Ontkean M, Gray R, Greenberg B. Diminished endothelium-derived
relaxing factor activity in an experimental model of chronic heart
failure. Circ Res 1991;69:1088–96.
6. Drexler H, Hayoz D, Mu¨nzel T, et al. Endothelial function in chronic
congestive heart failure. Am J Cardiol 1992;69:1596–601.
7. Qi XL, Stewart DJ, Gosselin H, et al. Improvement of endocardial
and vascular endothelial function on myocardial performance by
captopril treatment in postinfarct rat hearts. Circulation 1999;100:
1338–45.
8. Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and
congestive heart failure. Br Heart J 1991;65:245–8.
9. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress
in patients with congestive heart failure. J Am Coll Cardiol 1998;31:
1352–6.
10. Bouloumie´ A, Bauersachs J, Linz W, et al. Endothelial dysfunction
coincides with an enhanced NO synthase expression and superoxide
anion production. Hypertension 1997;30:934–41.
11. Bauersachs J, Bouloumie´ A, Fraccarollo D, Hu K, Busse R, Ertl G.
Endothelial dysfunction in chronic myocardial infarction despite
increased vascular endothelial nitric oxide synthase and soluble gua-
nylyl cyclase expression: role of enhanced vascular superoxide produc-
tion. Circulation 1999;100:292–8.
12. Drexler H. Endothelium as a therapeutic target in heart failure.
Circulation 1998;98:2652–5.
13. Drexler H, Kurz S, Jeserich M, Mu¨nzel T, Hornig B. Effect of
chronic angiotensin-converting enzyme inhibition on endothelial
function in patients with chronic heart failure. Am J Cardiol
1995;76:13E–8E.
14. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects
of quinaprilat and enalaprilat on endothelial function of conduit
arteries in patients with chronic heart failure. Circulation 1998;98:
2842–8.
15. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones
regulating cardiovascular function in patients with severe congestive
heart failure and their relation to mortality. Circulation 1990;82:
1730–6.
16. Staessen J, Lijnen P, Fagard R, Verschuren L, Amery A. Rise in
plasma concentration of aldosterone during long-term angiotensin II
suppression. J Endocrinol 1981;91:457–65.
17. Pitt B, Zannad F, Remme WJ, et al, the Randomized ALdactone
Evaluation Study Investigators. The effect of spironolactone on mor-
bidity and mortality in patients with severe heart failure. N Engl J Med
1999;341:709–17.
18. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide
bioactivity, improves endothelial vasodilator dysfunction, and sup-
presses vascular angiotensin I/angiotensin II conversion in patients
with chronic heart failure. Circulation 2000;101:594–7.
19. Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ
M. Striking increase of natriuresis by low-dose spironolactone in
congestive heart failure only in combination with ACE-inhibition:
mechanistic evidence to support RALES. Circulation 2000;102:
2325–8.
20. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic
endothelin receptor blockade attenuates progressive ventricular dilata-
tion and improves cardiac function in rats with myocardial infarction:
possible involvement of myocardial endothelin system in ventricular
remodeling. Circulation 1997;96:3963–73.
21. Bauersachs J, Bouloumie´ A, Mu¨lsch A, Wiemer G, Fleming I,
Busse R. Vasodilator dysfunction in aged spontaneously hyperten-
sive rats: changes in NO synthase III and soluble guanylyl cyclase
expression, and in superoxide anion production. Cardiovasc Res
1998;37:772–9.
22. Bauersachs J, Fraccarollo D, Galuppo P, Widder J, Ertl G. Endothelin
receptor blockade improves endothelial vasomotor dysfunction in heart
failure. Cardiovasc Res 1998;47:142–9.
23. Skatchkov M, Mu¨nzel T. Validation of lucigenin as a chemilumines-
cent probe to monitor vascular superoxide as well as basal vascular
nitric oxide production. Biochem Pharmacol 1999;254:319–24.
24. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves
endothelial function of conduit arteries in patients with chronic heart
failure. Circulation 1998;97:363–8.
25. Mulder P, Elfertak L, Richard V, et al. Peripheral artery structure and
endothelial function in heart failure. Am J Physiol 1996;271:H469–
77.
26. Drexler H, Lu W. Endothelial dysfunction of hindquarter resistance
vessels in experimental heart failure. Am J Physiol 1992;262:
H1640–5.
27. Comini L, Bachetti T, Gaia G, et al. Aorta and skeletal muscle NO
synthase expression in experimental heart failure. J Mol Cell Cardiol
1996;28:2241–8.
28. Smith CJ, Sun D, Hoegler C, et al. Reduced gene expression of
vascular endothelial NO synthase and cyclooxygenase-1 in heart
failure. Circ Res 1996;78:58–64.
357JACC Vol. 39, No. 2, 2002 Bauersachs et al.
January 16, 2002:351–8 Spironolactone Improves Endothelial Dysfunction in CHF
29. Ushio-Fukai M, Zafari AM, Fukui T, Ishazaka N, Griendling KK.
p22phox is a critical component of the superoxide-generating NADH/
NADPH oxidase system and regulates angiotensin II-induced hyper-
trophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317–
21.
30. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. An-
giotensin II stimulates NADH and NADPH oxidase activity in
cultured vascular smooth muscle cells. Circ Res 1994;74:1141–8.
31. Wollert KC, Studer R, von Bu¨low B, Drexler H. Survival after
myocardial infarction in the rat: role of tissue angiotensin-converting
enzyme inhibition. Circulation 1994;90:2457–67.
32. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular super-
oxide production and vasomotor function in hypertension induced by
deoxycorticosterone acetate-salt. Circulation 2000;101:1722–8.
33. Wiemer G, Linz W, Hatrik S, Scho¨lkens BA, Malinski T.
Angiotensin-converting enzyme inhibition alters nitric oxide and
superoxide release in normotensive and hypertensive rats. Hyperten-
sion 1997;30:1183–90.
34. Yang BC, Li DY, Weng YF, Lynch J, Wingo CS, Mehta JL.
Increased superoxide anion generation and altered vasoreactivity
in rabbits on low-potassium diet. Am J Physiol 2000;274:H1955–
61.
35. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-
spirolactone derivatives: characterization in vivo and in vitro. J Phar-
macol Exp Ther 1987;240:650–6.
36. Ide T, Tsutsui H, Kinugawa S, et al. Direct evidence for increased
hydroxyl radicals originating from superoxide in the failing myocar-
dium. Circ Res 2000;86:152–7.
358 Bauersachs et al. JACC Vol. 39, No. 2, 2002
Spironolactone Improves Endothelial Dysfunction in CHF January 16, 2002:351–8
